International Journal of Medicinal Mushrooms

ISSN for PRINT: 1521-9437

For Online Access

Best Paper Award Selection - Editorial Board Site

2003, Volume5

Issue 1

102 pages

DOI: 10.1615/InterJMedicMush.v5.i1

Issue price - $128.00

Carine Bezivin
Laboratoire de Pharmacognosie et Mycologie, Faculte de Pharmacie, UPRES EA 2234, 2 Av. du Pr. L. Bernard, 35043 Rennes Cedex, France

Jean-Guy Delcros
Groupe de Recherche en Therapeutique Anticancereuse, Faculte de Medecine, CNRS FRE 2261, 2 Av. du Pr. L. Bernard, 35043 Rennes Cedex, France

Helene Fortin
Laboratoire de Pharmacognosie et Mycologie, Faculte de Pharmacie, UPRES EA 2234, 2 Av. du Pr. L. Bernard, 35043 Rennes Cedex, France

Maryvonne Amoros
Laboratoire de Pharmacognosie et Mycologie, Faculte de Pharmacie, UPRES EA 2234, 2 Av. du Pr. L. Bernard, 35043 Rennes Cedex, France

Joel Boustie
Laboratoire de Pharmacognosie et Mycologie, Faculte de Pharmacie, UPRES EA 2234, 2 Av. du Pr. L. Bernard, 35043 Rennes Cedex, France

The antitumor activity of a crude extract of the mushroom Lepista inversa (Scop.: Fr.) Pat. Was studied against intraperitoneally transplanted lymphocytic leukemia (L1210) and intramuscularly transplanted Lewis lung carcinoma (3LL) in mice. The 50% lethal dose was determined to be about 500 mg/kg for an i.p. administration of the extract. Intraperitoneal administration of 75 mg/kg of body weight/day of the extract increased the lifespan of L1210 and 3LL tumor-bearing mice by 50% and 14%, respectively, with respect to the control group. The antileukemic activity against the L1210 model in mice was considered to be significant.

Download article, 6 pages

Article price - $35.00

<< Previous article   Next article >>